This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


David K. Lee
Chief Executive Officer at Servier Pharmaceuticals


David K. Lee is CEO of Servier Pharmaceuticals, a commercial-stage pharmaceuticals company with a passion for innovation and improving the lives of patients and their families and caregivers. David is a seasoned veteran of the pharma industry and is dedicated to bringing innovative, responsible and life-changing products to oncology and rare disease patients around the globe. As CEO, David leads Servier Pharmaceuticals’ efforts to leverage Servier Group’s international portfolio and seek acquisitions, licensing deals and partnerships in the United States—a new frontier for the France-based global pharmaceutical company.

Throughout his career, David has held leadership positions at several industry-leading companies, including Shire, Baxalta and Novartis. Most recently, he served as Shire’s Head of the Global Genetic Disease and Oncology franchises, where he oversaw the cross-functional leadership teams responsible for strategy, marketing, business assessment and planning. His career-highlights include the approval of products for oncology (acute lymphoblastic leukemia and metastatic pancreatic cancer) and genetic diseases (hereditary angioedema). David also guided Servier’s acquisition of the Shire Oncology portfolio.

Energized by his long-held mission to find cures for cancer and rare diseases, David spent time early in his career working at Partners in Health in Rwanda, the World Health Organization in Geneva, and the Boston Medical Library. While at Novartis, he helped launch novel vaccines and orchestrated the successful cross-functional completion of three Phase I trials, two Phase II trials, and a Phase III registration trial. He has a passion for open innovation that feeds his commitment to identifying meaningful partnerships across the healthcare spectrum, with the goal of fostering next generation scientific discovery that will have lasting social impact in the United States and, ultimately, around the world.

David graduated magna cum laude from Harvard College with a degree in Biochemistry and later received his MBA from Harvard Business School. An outdoorsman and family-man, David spends his time outside of work on adventures with his family and friends.

Agenda Sessions

  • Keynote Address: Improving Patients' Lives & Re-Defining Value